A pharmaceutical multi-agent system must never recommend off-label drug uses or invent clinical claims. Generic toxicity filters catch insults but miss domain violations. How should the team design guardrails and validation?
Select an answer to reveal the explanation.
Short Explanation
The correct answer is D. Pharma needs custom domain guardrails for off-label and uncited claims, proven with synthetic adversarial tests—not just generic toxicity filters. Base-model safety is too coarse. Letting users override twice is not a control. Latin translations are not a compliance strategy.
Full Explanation
Option D is correct. Skills include custom guardrails for domain-specific constraints and guardrail testing with synthetic data. Generic toxicity filters do not encode pharmaceutical labeling rules; explicit detectors plus synthetic adversarial validation close that gap before release.
Option A is incorrect because general safety training does not reliably enforce specialized regulatory content policies.
Option B is incorrect because user insistence must not bypass clinical safety policies.
Option C is incorrect because obfuscation hinders audit and does not enforce correct medical content.